Latest Licensing And Partnerships News

Vectus Biosystems has had its ASX trading suspension lifted following the disclosure of a significant transaction involving a compound from its drug library, signaling renewed investor interest.

Echo IQ’s application for a Category III CPT code was declined by the AMA, but the company is exploring reconsideration and new AI-specific coding frameworks to advance US reimbursement.

Echo IQ has completed its presentation to the CPT Editorial Panel for a Category III CPT code for EchoSolv AS, with a decision expected from the American Medical Association in the coming weeks. Meanwhile, the company is advancing US deployments and FDA clearance efforts.

Neurotech International reported a 23% revenue drop and a doubling of its net loss to $10.6 million for FY25, driven by reduced R&D grants and high development costs. Despite financial pressures, the company marked significant clinical and regulatory progress for its NTI164 cannabinoid therapy.

Biotron Limited reported a significantly reduced net loss of $318,572 for FY2025, bolstered by a $1.27 million capital raise and a $1.81 million R&D tax rebate, as it advances clinical and preclinical antiviral programs.

Metallium Ltd has partnered with Rice University to advance its Flash Joule Heating technology, targeting a breakthrough in rare earth element separation that could reduce Western dependence on Chinese refining. This collaboration seeks to simplify or bypass the costly solvent extraction process dominating the industry.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.

BPH Global has launched a focused R&D collaboration with Temasek Polytechnic to develop seaweed-based bio-stimulants aimed at boosting growth and yields in Southeast Asia's oil palm and rice sectors. Early talks are also underway for a production facility in Indonesia to commercialize these innovations.

Echo IQ’s application for a key US procedural code was rejected but the company plans a swift resubmission, maintaining confidence in its US commercial rollout.

Algorae Pharmaceuticals has partnered with Peter MacCallum Cancer Centre to validate AI-predicted drug combinations across multiple cancer types, aiming to accelerate its oncology pipeline development.

Unibail-Rodamco-Westfield and Cenomi Centers have entered a decade-long exclusive partnership to bring the Westfield brand to Saudi Arabia’s premier shopping centres, aiming to reshape retail experiences across the Kingdom’s largest cities.

Starpharma reports steady progress in its DEP® drug development programs, launches new marketing campaigns in key regions, and maintains a strong cash position of $17.2 million as it refines clinical strategies and partnerships.